Skip to main content

Table 7 Risk factor analysis for major bleeding occurrence within 1 year after lung cancer diagnosis

From: Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study

  

Univariate

Multivariate**

  

sHR (95% CI)

p-value

sHR (95% CI)

p-value

Age

<  65

≥ 65

1.38 (1.11–1.71)

0.004

1.40 (1.11–1.76)

0.005

Gender

Male

Female

0.68 (0.53–0.87)

0.002

0.73 (0.57–0.94)

0.016

Metastasis

 

1.58 (1.26–1.98)

< 0.0001

1.38 (1.08–1.78)

0.011

PE

 

2.88 (1.83–4.52)

< 0.0001

2.90 (1.85–4.54)

< 0.0001

DVT

 

1.53 (0.96–2.43)

0.074

  

Anticoagulant therapy

 

1.91 (1.41–2.59)

< 0.0001

1.77 (1.30–2.43)

0.0003

Antiplatelet therapy

 

1.36 (1.09–1.71)

0.007

1.27 (1.01–1.60)

0.044

NSAID therapy

 

0.71 (0.49–1.03)

0.075

  

Lung cancer surgery

 

1.79 (1.33–2.42)

0.0001

2.54 (1.88–3.45)

< 0.0001

Other surgery

 

1.68 (1.26–2.23)

0.0004

1.50 (1.11–2.02)

0.009

Chemotherapy

 

1.66 (1.30–2.13)

< 0.0001

1.54 (1.19–2.00)

0.001

Bevacizumab

 

1.04 (0.49–2.21)

0.919

  

Oral targeted therapy

 

0.97 (0.47–1.97)

0.925

  

Radiotherapy

 

1.80 (1.34–2.41)

0.0001

1.71 (1.25–2.34)

0.001

  1. **Multivariate analysis adjusted for age and gender